Macrolides (alone or in combination) should be used as first-line empirical therapy of community-acquired pneumonia in children: myth or maxim?

Adilia Warris

Source: Breathe, 17 (3) 835; 10.1183/20734735.0056-2021
Journal Issue: September

Congress or journal article abstractFull text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Adilia Warris. Macrolides (alone or in combination) should be used as first-line empirical therapy of community-acquired pneumonia in children: myth or maxim?. Breathe, 17 (3) 835; 10.1183/20734735.0056-2021

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Macrolide combination therapy for patients hospitalised with community-acquired pneumonia? An individualised approach supported by machine learning
Source: Eur Respir J, 54 (6) 1900824; 10.1183/13993003.00824-2019
Year: 2019



Combination versus monotherapy for nosocomial pneumonia
Source: Eur Respir Rev 2007; 16: 50-55
Year: 2007



Should macrolides be given to all patients with community-acquired pneumonia? Con argument
Source: International Congress 2017 – Controversies in community-acquired pneumonia: a pro and con debate
Year: 2017


Should macrolides be given to all patients with community-acquired pneumonia? Pro argument
Source: International Congress 2017 – Controversies in community-acquired pneumonia: a pro and con debate
Year: 2017


Monotherapy with β-lactamic antibiotics or macrolides vs their combination for the treatment of community acquired pneumonia (CAP)
Source: Annual Congress 2008 - Lower respiratory tract infection: from outbreak to prognostic tests
Year: 2008


Are corticosteroids useful in community-acquired pneumonia?
Source: Annual Congress 2006 - Evaluation of risk factors in community-acquired pneumonia
Year: 2006


Corticosteroids for community-acquired pneumonia: are we still there?
Source: International Congress 2019 – Severe pneumonia: epidemiology, mechanisms and treatment
Year: 2019


Clinical stability and switch therapy in hospitalised patients with community-acquired pneumonia: are we there yet?
Source: Eur Respir J 2013; 41: 5-6
Year: 2013


Cost-effective antibiotic management of community acquired pneumonia
Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=198
Year: 2004

Changes in empirical initial antibiotic therapy in community-acquired pneumonia: assessment of clinical failure versus discordant therapy
Source: Eur Respir J 2006; 28: Suppl. 50, 736s
Year: 2006

Inhaled antibiotics in ventilator-associated pneumonia: treatment or prophylaxis?
Source: International Congress 2016 – PG13 Inhaled antibiotics in respiratory infections
Year: 2016



Pneumococcal pneumonia: an old disease with radically-new approaches for antibiotic therapy
Source: Annual Congress 2005 - Outcome in severe pneumonia
Year: 2005

Determinants of prescription and choice of empirical therapy for hospital-acquired and ventilator-associated pneumonia
Source: Eur Respir J 2011; 37: 1332-1339
Year: 2011



Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia
Source: Eur Respir J 2003; 21: 135-143
Year: 2003



Comparison of ampicillin-sulbactam/macrolide dual therapy versus fluoroquinolone monotherapy in hospitalized patients with community-acquired pneumonia
Source: International Congress 2015 – Clinical issues in CAP: microbiological and radiological determinants
Year: 2015

Cost-effectiveness of full-course oral levofloxacin in severe community-acquired pneumonia
Source: Eur Respir J 2004; 24 : 644-648
Year: 2004



Low-dose corticosteroids during severe community-acquired pneumonia: end of the story
Source: Eur Respir J 2015; 45: 305-307
Year: 2015


Community-acquired paediatric pneumonia (CAPP). Is antibiotic treatment universally required?
Source: Eur Respir J 2001; 18: Suppl. 33, 171s
Year: 2001

How often can we use short course therapy in patients with hospital-acquired pneumonia?
Source: Eur Respir J 2007; 30: Suppl. 51, 408s
Year: 2007